logo-loader
RNS
Kromek Group PLC

Kromek Group PLC - Kromek Signs Agreements with Siemens Healthineers

RNS Number : 1926V
Kromek Group PLC
30 January 2025
 

30 January 2025

 

Kromek Group plc 

("Kromek" or the "Company" or the "Group") 

 

Kromek Signs Agreements with Siemens Healthineers

Non-exclusive IP licensing and CZT production enablement agreements to generate $37.5m

Kromek expected to become profitable for FY 2025

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, is pleased to announce that it has entered into multi-year agreements with Siemens Medical Solutions USA, Inc. ("Siemens Healthineers") to provide know-how and use rights of IP on a non-exclusive basis, as well as furnaces and related services, under an Enablement Agreement and Patent Licensing Agreement, and also for the Group to supply CZT-based detector tiles (the "Supply Agreement") (together with the Enablement and Patent Licensing Agreements, the "Agreements") to enable the production of CZT detectors for SPECT application (single-photon emission computed tomography).

 

Under the Enablement Agreement, the Group will be paid a total of $37.5m in cash in four installments over a four-year period, with the first installment of $25.0m to be received in the current financial year, a material amount of which will be recognised as revenue. In addition, the Directors believe the Supply Agreement will make a material contribution to Advanced Imaging revenue from the second year of the agreement onwards.

 

Summary

·    Over a four-year period, Kromek will:

o    transfer 15 of its existing 174 furnaces for CZT production to Siemens Healthineers

o  provide Siemens Healthineers with all know-how, IP and related services for CZT-based SPECT detector production

·    The Group has licensed to Siemens Healthineers its patents related to CZT production for SPECT applications

·    All know-how and IP will be provided and licensed on a non-exclusive basis. Accordingly, Kromek is unencumbered from continuing to utilise its know-how and IP and supplying other OEMs in SPECT or other advanced imaging markets

·    Kromek is expected to supply Siemens Healthineers with CZT-based detector tiles over the four-year period under the Supply Agreement

·   The Group expects to report revenue growth for the current financial year and profit significantly ahead of market expectations, with a much strengthened balance sheet

 

Enablement and Patent Licensing Agreements

Kromek will transfer title of 15 of its furnaces (the "Transfer Furnaces") for the production of CZT, which are currently sited in the Group's UK facility, to Siemens Healthineers. The Group will enable the physical relocation of the Transfer Furnaces to a Siemens Healthineers facility, which is expected to occur at the end of the four-year period of the Enablement Agreement. Prior to the relocation, the Group will use the Transfer Furnaces to deliver the CZT-based detector tiles under the Supply Agreement.

 

Over a four-year period, commencing immediately, the Group will provide Siemens Healthineers with its know-how and IP regarding the production of CZT-based detector tiles for SPECT applications and services required to enable such production. Kromek has licensed in perpetuity its patents relevant for producing CZT-based detectors for SPECT applications on a non-exclusive basis. Kromek retains ownership of the patents. Under the terms of the Agreements, the Group is entitled to continue to exercise all its know-how and IP and to serve the global SPECT market for CZT-based detectors.

 

Supply Agreement

Kromek is set to supply its CZT-based detector tiles to Siemens Healthineers for the duration of the Enablement Agreement, which may be extended for an additional year at Siemens Healthineers' discretion. This multi-year agreement is projected to significantly contribute to revenue, complementing the $37.5m to be received under the Enablement Agreement for the Advanced Imaging Division, throughout the agreement period.

 

Under the terms of the Supply Agreement, Kromek will manufacture the CZT-based detector tiles and will be responsible for providing all necessary capital equipment, engineering, manufacturing technology, as well as the equipment and facilities required to fulfil the agreement.

   

Benefit to Kromek

Kromek plans to utilise the initial $25.0m installment to support delivery under the Enablement Agreement, reduce its debt and significantly strengthen its balance sheet. As a result of the Agreements and recognising a material amount of the first installment under the Enablement Agreement as revenue in FY 2025, the Group expects to become profitable in the current year, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond FY 2025 while delivering sustainable profits.

 

Additionally, the Enablement Agreement does not restrict Kromek from seeking other potential collaborations, including similar ventures with other OEMs in advanced imaging markets. As the largest independent producer and supplier of CZT, Kromek intends to continue producing CZT for the SPECT and CT (computed tomography) markets, utilising the remaining 159 furnaces it owns.

 

Arnab Basu, Chief Executive Officer of Kromek, said: "We are delighted to have entered into these agreements with Siemens Healthineers, a move that underscores Kromek's position as the largest independent producer of CZT and CZT-based detectors. We both have an ongoing commitment to innovation that is critical for developing superior detector solutions that play a vital role in the early detection of serious illnesses. Both Siemens Healthineers and Kromek are aligned in our vision to enhance healthcare through technological advancements, and we eagerly anticipate collaborating to bring this vision to fruition.


"The initial $25.0m payment will be used to support the delivery of various milestones under the agreements, significantly reduce our debt and strengthen our balance sheet, ultimately enhancing our operational capabilities. These significant agreements enable Kromek to report FY 2025 profit ahead of market expectations and lay the groundwork for further growth in revenues and sustainable profitability beyond that period. These agreements also enable Kromek to continue its leadership in CZT production for SPECT and CT markets, as we maintain the flexibility to explore further collaborations with other OEMs in advanced imaging."

 

For further information, please contact: 

  

Kromek Group plc 


Arnab Basu, CEO 

Paul Farquhar, CFO 

+44 (0)1740 626 060 

 


Cavendish Capital Markets Limited (Nominated Adviser and Broker)  

  

Geoff Nash/Giles Balleny/Seamus Fricker- Corporate Finance 

Tim Redfern- ECM

Michael Johnson/Tamar Cranford-Smith - Sales

+44 (0)20 7220 0500 

 



Gracechurch Group (Financial PR) 


Harry Chathli/Claire Norbury/Henry Gamble 

+44 (0)20 4582 3500 

 

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Paul Farquhar, Chief Financial Officer.

 

Kromek Group plc 

 

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.  

 

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.  

 

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.  

 

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.  

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.  

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRBCGDBIGDDGUC
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

7 min read